CONMED Corp Files 8-K: Director & Officer Changes
Ticker: CNMD · Form: 8-K · Filed: Aug 14, 2024 · CIK: 816956
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing-update
Related Tickers: CNMD
TL;DR
CONMED filed an 8-K for director/officer changes and comp plans.
AI Summary
CONMED Corporation filed an 8-K on August 14, 2024, reporting changes in its board of directors and executive officers, as well as updates to compensatory arrangements. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Largo, Florida.
Why It Matters
Changes in a company's board and executive team can signal shifts in strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing is routine and reports standard corporate governance and compensation information.
Key Numbers
- 001-39218 — SEC File Number (Identifies the company's filings with the SEC.)
- 16-0977505 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- CONMED Corporation (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Largo, FL (location) — Principal executive offices
FAQ
What specific changes were made to CONMED Corporation's board of directors or executive officers?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers', but the specific details of these changes are not provided in the provided text.
What are the key details of the compensatory arrangements mentioned in the filing?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item reported, but the specific details of these arrangements are not included in the provided text.
When was this 8-K report filed with the SEC?
The report was filed on August 14, 2024.
What is CONMED Corporation's principal business address?
CONMED Corporation's principal executive offices are located at 11311 Concept Blvd, Largo, FL 33773.
What is CONMED Corporation's standard industrial classification code?
CONMED Corporation's Standard Industrial Classification code is 3845, which corresponds to ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS.
Filing Stats: 435 words · 2 min read · ~1 pages · Grade level 12.9 · Accepted 2024-08-14 16:37:58
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value CNMD NYSE Indicate by ch
Filing Documents
- d819774d8k.htm (8-K) — 21KB
- 0001193125-24-200674.txt ( ) — 136KB
- cnmd-20240814.xsd (EX-101.SCH) — 3KB
- cnmd-20240814_lab.xml (EX-101.LAB) — 17KB
- cnmd-20240814_pre.xml (EX-101.PRE) — 11KB
- d819774d8k_htm.xml (XML) — 3KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 CONMED CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-39218 16-0977505 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 11311 Concept Blvd Largo , FL 33773 (Address of principal executive offices, including zip code) (727) 392-6464 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value CNMD NYSE Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b)(2) On August 14, 2024, CONMED Corporation (the "Company") announced that the employment of Stanley W. (Bill) Peters, the Company's President, Advanced Surgical & Advanced Endoscopic Technologies, will terminate on August 31, 2024. In connection with his departure, Mr. Peters will receive the compensation and benefits payable on a non-change in control qualifying termination under the Company's Executive Severance Plan, as described in the Company's Proxy Statement filed with the Securities and Exchange Commission on April 8, 2024. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CONMED CORPORATION (Registrant) By: /s/ Curt R. Hartman Name: Curt R. Hartman Title: President and Chief Executive Officer Date: August 14, 2024